ReviewFrontiers in medicine2020
Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 87 citations in OpenAlex.
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic insights into one carbapenem-resistant and multidrug-resistantMicrobiology spectrum · 2026Article
- Evaluation of Beta-Lactamase-Producing Strains Isolated in a Tertiary Nephrology Hospital in Romania.Antibiotics (Basel, Switzerland) · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Genome-Wide In Silico Analysis of the Type VI Secretion System (T6SS) Within the Morganella Genus.MicrobiologyOpen · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
- Carbapenem and colistin-resistantJAC-antimicrobial resistance · 2026Article
- Multiplex real-time PCR with high-resolution melting analysis for rapid identification of carbapenem and colistin resistance genes in clinical Enterobacterales isolates.Scientific reports · 2026Article
- Ambler class C-type β-lactamases and porin alterations in Enterobacter cloacae complex and Klebsiella aerogenes in the Netherlands, 2012-2023.BMC microbiology · 2026Article
- Genomic epidemiology of carbapenemase-producingMicrobial cell (Graz, Austria) · 2026Article
- Dissemination of aFrontiers in microbiology · 2026Article
- Genetic Basis of Multiple Antibiotic Resistance of PathogenicInternational journal of molecular sciences · 2025Article
- Carbapenem resistance in aAntimicrobial agents and chemotherapy · 2025Article
- Beyond the Spotlight:Antibiotics (Basel, Switzerland) · 2025Review
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Development of phenotypic and genotypic methods for the identification of NmcA β-lactamases in carbapenem-resistantMicrobiology spectrum · 2025Article
- Water-Mediated Dissemination and Detection of Antibiotic Resistance Across Livestock, Agri-Food, and Aquaculture Systems.Micromachines · 2025Review
- MALDI-TOF lipidomics rapidly detects modification of 2-hydroxymyristate lipid A, a potential virulence trait inMicrobiology spectrum · 2025Article
- Carbapenem-resistantMicrobiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative bacteria, especially Enterobacterales, have emerged as major players in antimicrobial resistance worldwide. Resistance may affect all major classes of anti-gram-negative agents, becoming multidrug resistant or even pan-drug resistant. Currently, β-lactamase-mediated resistance does not spare even the most powerful β-lactams (carbapenems), whose activity is challenged by carbapenemases. The dissemination of carbapenemases-encoding genes among Enterobacterales is a matter of concern, given the importance of carbapenems to treat nosocomial infections. Based on their amino acid sequences, carbapenemases are grouped into three major classes. Classes A and D use an active-site serine to catalyze hydrolysis, while class B (MBLs) require one or two zinc ions for their activity. The most important and clinically relevant carbapenemases are KPC, IMP/VIM/NDM, and OXA-48. However, several carbapenemases belonging to the different classes are less frequently detected. They correspond to class A (SME-, Nmc-A/IMI-, SFC-, GES-, BIC-like…), to class B (GIM, TMB, LMB…), class C (CMY-10 and ACT-28), and to class D (OXA-372). This review will address the genetic diversity, biochemical properties, and detection methods of minor acquired carbapenemases in Enterobacterales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.